Exosomal microRNAs isolated from plasma of mesenteric veins linked to liver metastases in resected patients with colon cancer

Mariano Monzo1,*, Sandra Santasusagna1,*, Isabel Moreno2, Francisco Martinez2, Raquel Hernández2, Carmen Muñoz1, Joan J. Castellano1, Josep Moreno2 and Alfons Navarro1

1 Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain
2 Department of Medical Oncology and Surgery, Hospital Municipal de Badalona, Badalona, Spain
* These authors have contributed equally to this article

Correspondence to: Mariano Monzo, email: mmonzo@ub.edu
Correspondence to: Alfons Navarro, email: anavarroponz@ub.edu

Keywords: exosomes, colon cancer, miR-328, microRNAs, tumor-draining vein

Received: February 17, 2017  Accepted: March 03, 2017  Published: March 10, 2017

ABSTRACT

Before reaching a peripheral vein (PV), miRNAs released by the tumor are diluted and dispersed throughout the body or even retained in a specific organ. We hypothesized that blood drawn from the tumor-draining vein could provide more homogeneous information than blood drawn from the PV as that blood would contain all the biomarkers released by the tumor before they reach a potential metastatic site. We have profiled 754 miRNAs in 15 colon cancer plasma samples from the tumor-draining vein, the mesenteric vein (MV), identifying 13 microRNAs associated with relapse. The prognostic impact of these miRNAs were validated in 50 MV and 50 paired PV plasma samples of stage I-III colon cancer patients. Four miRNAs, let-7g, miR-15b, miR-155 and miR-328, were found overexpressed in MV compared to PV, and patients with high levels of those miRNAs in MV plasma had shorter time to relapse. Interestingly, in patients developing liver metastases, the exosomal cargo of miR-328 was much greater in MV than in PV plasma indicating a possible role of miR-328 in the development of liver metastases. Our results indicate that in colon cancer, the primary tumor releases high concentrations of miRNAs through the MV, and some of them are contained in tumor derived exosomes.

INTRODUCTION

Colon cancer (CC) is the third most common cancer and the second cause of death from cancer in developed countries [1]. Disease stage is the primary prognostic factor for CC and surgery is the first therapeutic option for stages I-III - alone for stage I or followed by adjuvant chemotherapy in stage III. However, in patients with stage II disease, the benefit of adjuvant treatment is unclear [2]. While several studies have shown that oxaliplatin plus either 5-fluorouracil or capecitabine can prolong disease-free survival and overall survival by 20% in stage III patients [3, 4], the evidence in stage II patients is not so clearcut [5]. In recent years, the effect of the monoclonal antibodies cetuximab [6] and bevacizumab [7] has also been examined, but results have been less than satisfactory. There is thus a clear need for biomarkers that can predict relapse in patients with CC - particularly those with stage II disease - and thus help to identify patients likely to benefit from adjuvant therapy. Several circulating biomarkers have been examined in plasma or serum but findings are often inconsistent.

In recent years, microRNAs (miRNAs), non-coding RNAs that play a key role in the regulation of mRNA translation to protein, have emerged as promising biomarkers for screening, diagnosis and prognosis in several cancers, including CC. Several studies have found a link between miRNAs - either in tumor or in blood - and colorectal cancer. However, conflicting findings have been reported on the tumor expression levels of some miRNAs. For example, some studies have reported...
overexpression of miR-10, miR-23a, miR-34b, miR-150, miR-199b, miR-212, miR-296, miR-324, miR-331, miR-340, and let-7g in tumor samples, while others have reported underexpression of these miRNAs [8]. Moreover, differences in the expression level of the same miRNA are often observed between tumor and paired blood samples. For example, miR-92 was overexpressed in plasma [9] but underexpressed in tumor [10]. Similar inconsistencies were found in the expression of the miR-200 family, where high plasma expression of miR-200c was related to poor prognosis while high tumor expression of miR-200c was related to better prognosis [11].

More recent studies have focused on miRNAs associated with exosomes, small vesicles (30-100nm) that mediate cell-to-cell communication in a variety of biological processes. An exosome contains a small cytosol with both coding and non-coding RNAs, 40% of which are miRNAs [12]. Exosomes are secreted by several cell types and captured by receptor cells in many body fluids, where they regulate normal and pathological physiological processes. Exosomes play an active role in the metastatic process by modifying the surrounding stroma in order to prepare the tissue microenvironment for the anchoring of metastatic cells [13-15].

Studies analyzing the expression levels of exosomal miRNAs in blood samples report varying results, and no homogeneous miRNA profile for CC has been identified. For example, a recent study in serum samples found that the exosomal cargo of miR-17-92 cluster was associated with poor prognosis in metastatic patients with colorectal cancer [16], while another study in circulating exosomal miRNAs in metastatic colorectal cancer patients identified a set of completely different miRNAs that did not include the miR-17-92 cluster [17].

These inconsistent findings on miRNAs in tumor, biofluids, and exosomes in CC have been attributed to various causes, including different patient populations, internal controls, and laboratory methods [8]. However, one potential factor that has not been fully examined is the anatomic route that exosomes and their biomarker cargos take in order to colonize a target organ.

All studies examining biomarkers in blood have used blood samples drawn from a peripheral vein (PV) in the forearm. However, we hypothesize that this method limits the correct interpretation of results, since before reaching the forearm, potential biomarkers released by the tumor are diluted and dispersed in other parts of the body or even retained in a specific organ. For example, exosomal biomarkers released by a colon tumor may be retained in the liver and not continue their circulatory route to the forearm. In contrast, blood drawn from a mesenteric vein (MV) close to the tumor site may well contain all the biomarkers released by the tumor before they reach the potential metastatic site [18].

In order to test this hypothesis, we have profiled the miRNA expression in plasma samples taken from MV of surgically resected stage I-III CC patients and identified several MV-miRNAs associated with time to relapse (TTR). Furthermore, we confirm that these miRNAs were contained in MV-exosomes.

RESULTS

Patients

Fifty patients were included in the study. Mean age was 72 years, and 31 (62%) were males. Thirty-five patients had stage I-II disease. Of the 15 patients who developed metastases (5 stage II and 10 stage III), eight had liver metastases and seven had metastases in other organs. Mean follow-up was 45.2 months (range 26.4-63.8). K-ras mutations were assessed in 44 patients (Table 1).

Identification of miRNAs associated to relapse

The analysis of 754 miRNAs in 15 MV samples allowed us to identify 13 miRNAs differentially expressed between relapsed vs non-relapsed patients. High MV expression of these miRNAs were associated with higher risk of relapse: let-7g (p = 0.008), miR-15b (p = 0.01), miR-18b (p = 0.04), miR-26a (p = 0.04), miR-106b (p = 0.04), miR-126 (p = 0.04), miR-142-3p (p = 0.04), miR-155 (p = 0.01), miR-328 (p = 0.02), miR-410 (p = 0.03), miR-449 (p = 0.03), miR-548c-5p (p = 0.04) and miR-744 (p = 0.02).

Expression levels of relapse-associated miRNAs in MV and PV

Of the 13 relapse-associated miRNAs identified, four were expressed at higher levels in MV than in PV plasma: let-7g (p = 0.002); miR-15b (p = 0.04); miR-155 (p = 0.05); miR-328 (p = 0.002) (Figure 1A-1D). The Hierarchical cluster analysis of these four miRNAs confirmed that all four miRNAs obtained from MV had higher levels of expression than those obtained from PV (Fisher’s exact p = 0.01) (Figure 1E). An association was observed between the MV expression levels of these four miRNAs and tumor site (let-7g: p = 0.03; miR-15b: p = 0.001; miR-155: p = 0.03; miR-328: p = 0.002) (Supplementary Figure 1). In addition, let-7g expression in MV was also associated with the presence of pre-existing polyps (p = 0.03), and miR-328 expression in MV was associated with disease stage (p = 0.07), and K-ras mutations (p = 0.04). There was no association between PV expression levels and clinical characteristics (Table 1).
Plasma miRNA expression and TTR

High MV expression of let-7g, miR-15b, miR-155 and miR-328 was associated with shorter TTR. Mean TTR was not reached for patients with low or high expression of let-7g ($p = 0.05$). TTR was 58.9 months (95% CI 52.6-65.3 months) for those with low levels of miR-15b, compared to 38.7 months (95% CI 29.9-47.6 months) for those with high levels ($p = 0.004$). TTR was 59.4 months (95% CI 53.5-65.2 months) for those with low levels of miR-155.

**Figure 1:** let-7g A., miR-15b B., miR-155 C. and miR-328 D. expression levels (fold change) in plasma from the peripheral vein (PV) and paired mesenteric vein (MV) of colon cancer patients. E. Heat map showing the miRNAs differentially expressed between PV and MV plasma samples clustered by Euclidean similarity metric (Fisher’s exact $p = 0.014$). Each row represents one miRNA and each column represents a plasma sample. The legend on the right indicates the miRNA represented in the corresponding row. The relative miRNA expression is depicted according to the color scale. Red indicates upregulation; green indicates downregulation and gray indicates no detection. PV or MV indicates the region where the sample was obtained and the number indicates each patient.
miR-155 and 41.1 months (95% CI 32.3-49.7 months) for those with high levels \((p = 0.01)\). TTR was 55.7 months (95% CI 49.3-62.1 months) for patients with low miR-328 expression, compared to 35.1 months (95% CI 26.1-44.1 months) for those with high expression \((p = 0.02)\) (Figure 2).

In contrast, inverse results were found when PV was analyzed. High PV expression of these four miRNAs was

**Table 1: Patient characteristics and univariate \(p\)-values for time to relapse and for let-7g, miR-15b, miR-155 and miR-328 expression levels in 50 patients with early-stage colon cancer.**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>(N) (%), (N=50)</th>
<th>(p)-value for association with microRNA expression</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(P) value (TTR)</td>
<td>let-7g</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MV Plasma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Plasma</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>31 (62)</td>
<td>0.674</td>
</tr>
<tr>
<td>Female</td>
<td>19 (38)</td>
<td></td>
</tr>
<tr>
<td>Median age</td>
<td>72</td>
<td>0.921</td>
</tr>
<tr>
<td>CEA levels</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(&lt;=5)</td>
<td>34 (68)</td>
<td>0.401</td>
</tr>
<tr>
<td>(&gt;5)</td>
<td>16 (32)</td>
<td></td>
</tr>
<tr>
<td>C 19.9 levels</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(&lt;=37)</td>
<td>46 (92)</td>
<td>0.478</td>
</tr>
<tr>
<td>(&gt;37)</td>
<td>4 (8)</td>
<td></td>
</tr>
<tr>
<td>Tumor location*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left colon</td>
<td>26 (52)</td>
<td>0.557</td>
</tr>
<tr>
<td>Right colon</td>
<td>24 (48)</td>
<td></td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(&lt;=5)</td>
<td>37 (74)</td>
<td>0.285</td>
</tr>
<tr>
<td>(&gt;5)</td>
<td>13 (26)</td>
<td></td>
</tr>
<tr>
<td>Histological type</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well differentiated</td>
<td>45 (90)</td>
<td>0.672</td>
</tr>
<tr>
<td>Poorly differentiated</td>
<td>5 (10)</td>
<td></td>
</tr>
<tr>
<td>Pre-existent polyp</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absent</td>
<td>38 (76)</td>
<td>0.666</td>
</tr>
<tr>
<td>Present</td>
<td>12 (24)</td>
<td></td>
</tr>
<tr>
<td>Perilymphatic invasion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absent</td>
<td>47 (94)</td>
<td>0.710</td>
</tr>
<tr>
<td>Present</td>
<td>2 (4)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>1 (2)</td>
<td></td>
</tr>
<tr>
<td>Adjuvant treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluoropyrimidines</td>
<td>28 (56)</td>
<td>0.405</td>
</tr>
<tr>
<td>None</td>
<td>22 (44)</td>
<td></td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-II</td>
<td>35 (70)</td>
<td>0.001</td>
</tr>
<tr>
<td>III</td>
<td>15 (30)</td>
<td></td>
</tr>
<tr>
<td>Lymph nodes examined</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(&lt;=12)</td>
<td>11(22)</td>
<td>0.266</td>
</tr>
<tr>
<td>(&gt;12)</td>
<td>39(78)</td>
<td></td>
</tr>
<tr>
<td>K-ras mutations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>14 (28)</td>
<td>0.79</td>
</tr>
<tr>
<td>No</td>
<td>30 (60)</td>
<td></td>
</tr>
<tr>
<td>Not assessed</td>
<td>6 (12)</td>
<td></td>
</tr>
<tr>
<td>Relapsed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>15 (30)</td>
<td>0.86</td>
</tr>
<tr>
<td>Hepatic metastasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>8 (16)</td>
<td>0.83</td>
</tr>
<tr>
<td>No</td>
<td>42 (84)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CEA, Carcinoma Embryonic Antigen; MV, mesenteric vein; PV, peripheral vein; TNM, Tumor, Nodule, Metastasis; TTR, time to relapse.

*Tumor location according to anatomical site: 17 ascending colon, 7 transverse colon, 6 descending colon and 20 sigmoid colon.*
associated with longer TTR. Mean TTR for patients with low let-7g expression was 28.7 months (95% CI 16.4-41.1 months), while it was 53.6 months (95% CI 47.3-59.9 months) for those with high expression ($p = 0.004$). TTR was 21.7 months (95% CI 6.7-36.7 months) for those with low levels of miR-15b, compared to 50.7 months (95% CI 44.3-57.1 months) for those with high levels ($p = 0.02$). TTR was 35.5 months (95% CI 29.9-48.1 months) for those with low levels of miR-155 and 52.9 months (95% CI 46.1-59.6 months) for those with high levels ($p = 0.03$). TTR was 42.3 months (95% CI 33.1-51.4 months) for patients with low miR-328 expression, compared to 56.1 months (95% CI 48.5-63.7 months) for those with high expression ($p = 0.03$) (Figure 3).

The multivariate analysis identified stage (HR = 0.08, 95% CI 0.02-0.32; $P < 0.001$) and high miR-328 expression in MV plasma (HR = 6.034, 95% CI 1.456-25; $p = 0.01$) as independent prognostic markers of TTR.

### miRNA cargo in exosomes isolated from MV and PV plasma

Sufficient plasma from both MV and PV to perform exosome isolation was only available from 33 patients (25 metastasis-free and eight with liver metastases). We captured images of round microvesicles with 30-100nm diameters in the exosome-rich fraction. Cryo-TEM and Western blot analyses confirmed the presence of exosomes in plasma samples (Figure 4A-4B). In the samples from all 33 patients, there were no differences in the exosome cargo of let-7g, miR-15b, miR-155 and miR-328 in MV versus PV plasma (Supplementary Figure 2). In order to examine whether the exosome cargo of these miRNAs was greater in patients with liver metastases, we then analyzed the subset of eight patients with metastases and found that the miR-328 cargo in exosomes was greater in MV than in PV ($p = 0.005$) (Figure 4C). Moreover, when we compared exosomes isolated from MV from patients with liver metastases and those without, the miR-328 cargo was higher in metastatic patients ($p = 0.03$) (Figure 4D), indicating that miR-328 is expressed at low levels in patients without liver metastases. In exosomes isolated from PV, there was no difference between the two groups of patients (Figure 4E).

### DISCUSSION

Metastases are the primary cause of death in cancer patients. Recent studies have found that the primary
tumor can release tumor-associated molecules into blood circulation, leading to the development of metastases in target organs [19]. Many investigators have examined the presence of miRNAs or exosomal miRNAs in plasma or serum samples from cancer patients [8, 11, 16, 17]. Since all biomarkers released by the primary tumor are released via veins, it is logical to suppose that more biomarkers would be located in veins close to the primary tumor. The large intestine is an optimal model to study exosome circulation due to its distinctive distribution of arteries and veins. Venous return of the colon occurs through the superior and inferior MVs, both of which flow into the hepatic portal vein, which carries blood to the liver. This anatomic distribution may explain the higher frequency of liver metastases associated with primary tumors located in the colon. For this reason, we have focused our study on patients with liver metastases. Furthermore, we have not included patients with rectal cancer, since the venous return of the rectum occurs through the iliac veins and does not flow into the liver.

In the present study, we have found that four miRNAs (let-7g, miR-15b, miR-155, miR-328) are more highly expressed in MV plasma than in PV plasma. Moreover, although all four miRNAs are associated with TTR, their overexpression in MV is related to poor prognosis, while their overexpression in PV is related to good prognosis. We can speculate that miRNAs with greater metastatic potential may be retained in the target organ, such as the liver, while those with less metastatic potential may continue to circulate towards the PV. Therefore, miRNAs isolated from PV blood would be more diluted than those from MV blood, have less metastatic potential, and thus indicate better prognosis (Figure 5). Moreover, the multivariate analysis identified overexpression of one of the miRNAs - miR-328 - in MV as an independent prognostic factor conferring a six-fold greater risk of relapse. Along these lines, a recent study in resected non-small-cell lung cancer patients found that tumor cells detected in the tumor-draining pulmonary vein were associated with relapse, while no association was found for tumor cells in the PV [20].

It is well known that exosomes and their cargo are one of the most important mediators of crosstalk between tumor cells and the microenvironment [21]. The presence

Figure 3: TTR according to let-7g A., miR-15b B., miR-155 C. and miR-328 D. expression levels (fold change) in plasma from the peripheral vein (PV).
Figure 4: Exosome characterization in plasma samples of colon cancer patients by Cryo-TEM A. and Western blot using TSG101 marker B. C. miR-328 expression levels (fold change) in exosomes from the peripheral vein (PV) and matched mesenteric vein (MV) of eight patients who developed liver metastases. D. miR-328 expression levels (fold change) in exosomes from the MV of patients with liver metastases compared to those without metastases. E. miR-328 expression levels (fold change) in exosomes from the PV of patients with liver metastases compared to those without metastases.

Figure 5: Anatomic route of miRNAs released by the primary colon tumor. Venous return of the colon occurs through the mesenteric veins (MV). Both MVs flow into the hepatic portal vein, which carries blood to the liver through the inferior cava vein before continuing to the peripheral veins (PVs). This anatomic distribution may explain the higher frequency of liver metastases associated with primary tumors located in the colon. 1, colon; 2, miRNA content in MV; 3, liver; 4, miRNA content in PV. Triangles indicate miRNAs with metastatic potential; ovals and diamonds indicate miRNAs without metastatic potential.
of exosomes in blood has been analyzed in several
tumors, including melanoma [22] and colorectal cancer
[16, 17], where blood samples were taken from the PV
of metastatic patients. Another study in metastatic ovarian
cancer assessed exosomes in ascitic liquid [23]. All these
studies found greater numbers of exosomes in plasma
from patients than from healthy controls [16, 17].

Interestingly, our study included only I-III stage CC
patients who had not developed metastases at the time of
entering the study. It would thus be logical to expect that
in these stages, the exosome cargo of our four miRNAs
(let-7g, miR-15b, miR-155 and miR-328), would be
greater in MV than in PV. However, when we analyzed
both relapsed and non-relapsed patients, we found no
overall significant differences in the miRNA cargo
between exosomes isolated from MV and PV plasma.
These findings are in line with those of previous studies
[11, 24, 25], where higher expression levels of miRNAs
in PV blood of metastatic patients was the manifestation
of all miRNAs released by both the primary tumor and the
metastasis.

In contrast, when we focused on the subset of
patients who relapsed and developed liver metastases,
while differences were still not found for let-7g, miR-
15b or miR-155, the miR-328 exosomal cargo was
much greater in MV than in PV. In addition, when the
exosomal cargo in MV plasma in patients who developed
liver metastases was compared to that in non-metastatic
patients, the miR-328 cargo was higher in those with
metastases. These findings lead us to suggest that the
presence of exosomes with miR-328 cargo in MV plasma
may well be an important predictor of metastases in CC
patients. Along these lines, overexpression of miR-328
was related to brain metastases in patients with non-small-
cell lung cancer [26].

There were more associations between miRNA
expression in MV than in PV and clinical characteristics.
In MV - but not PV - plasma, all four miRNAs were
associated with tumor site, let-7g was associated with
pre-existent polyp, and miR-328 was associated with
disease stage. These findings indicate that biomarkers
isolated from tumor-draining veins in patients with CC
may provide much more clinical information than those
from PVs.

Clearly, exosomes can help disseminate tumors and
develop metastases intraperitoneally via other anatomic
routes, including the lymphatic system. Tumors can
also shed cells directly into the peritoneal cavity or the
intestinal wall can be accidentally perforated during
surgery [23, 27]. Our findings show that obtaining
biomarkers from MV blood is a simple surgical method
that can complement clinical findings.

In summary, our findings indicate that expression
levels of let-7g, miR-15b, miR-155 and miR-328 isolated
from MV blood can be a useful tool to identify patients
at higher risk of relapse and that the miR-328 exosome cargo
in MV blood may play an important role in modulating
the tissue microenvironment for the anchoring of
metastatic cells. Our results provide the first step towards
obtaining more homogeneous results in the analysis of
blood biomarkers and can constitute an excellent surgical
method for identifying patients with CC who are at risk of
developing liver metastases.

MATERIALS AND METHODS

Patients

From August 2009 to August 2013, samples were
obtained from 50 patients with stage I-III CC who
underwent surgical resection at the Municipal Hospital
of Badalona (Badalona, Spain). Fifteen patients later
relapsed, eight of whom had liver metastases (Table 1).
All 50 patients had undergone a complete history and
physical examination prior to surgery. Approval for the
study was obtained from the institutional review board of
the hospital, and signed informed consent was obtained
from all patients in accordance with the Declaration of
Helsinki.

Blood samples

For all 50 patients, we obtained paired MV and PV
blood as previously described [18]. On the day of surgery,
5mL of blood was drawn from the PV and stored in
heparinized tubes. During surgery, with vascular ligation
before tumor resection, an additional 5mL of blood
was drawn from either the superior or the inferior MV,
according to the anatomic location of the tumor.

Sample processing and total RNA extraction

Plasma from all blood samples was obtained by
centrifugation of the whole blood at 5000G during 10 min
and saved frozen at -80°C until further use.

Total RNA was isolated from 250μl of plasma
using mirNeasy Mini Kit (Qiagen, Valencia, CA,
USA) according to the manufacturer’s protocol. The
concentration of total RNA was quantified using
NanoDrop ND-1000 spectrophotometer (Thermo
Scientific, Wilmington, DE, USA).

Supplementary Figure 3 shows the successive stages
of the miRNA analyses performed.

miRNA profiling

miRNA profiling of 754 different human miRNAs
was performed using TaqMan Array Human microRNA
Set Cards v3.0 (Applied Biosystems, Foster City, CA,
USA) in a training set of 15 MV and 3 PV plasma samples as previously described [28]. Briefly, RT reactions of 4.50μl contained: 0.80μl of 10X RT buffer (Applied Biosystems), 0.2μl dNTPs (100mM each), 1.5μl multiscribe reverse transcriptase (50 U/μl), 0.10μl RNase inhibitor (20 U/μl), 0.80μl Megaplex RT primers (10X), 0.90μl of MgCl₂ (25 U/μl) and 70ng of total RNA. RT reactions were incubated in a 2720 thermocycler (Applied Biosystems) for 2 min at 16ºC and 1 min at 42ºC for 40 cycles, 1 s at 50ºC and 5 min at 85ºC, and then held at 4°C. 2.5 μL of each RT product was preamplificated in order to increase the quantity of desired cDNA. Preamplification reactions were incubated in a 2720 thermocycler (Applied Biosystems) for 10 min at 95ºC, 2 min at 55ºC and 2 min at 72ºC; then 15 s at 95ºC and 4 min at 60ºC for 12 cycles, 10 min at 99.9ºC and then held at 4ºC. Preamplification product was diluted with 75μL of 0.1X TE buffer (pH 8.0). Quantitative real-time PCR reactions were performed on an ABI 7500 HT Sequence Detection System (Applied Biosystems) and contained 9μL of the diluted preamplificated product, 450μL of TaqMan Universal PCR Master Mix, No AmpErase UNG 2X (Applied Biosystems) and 441μL of nuclease-free water, mixed by vortexing, and pipetted into microfluidic TaqMan Human miRNA Array A and B.

Filtering and normalization of miRNA data

All miRNAs that were not expressed in all 15 MV plasma samples or were expressed with an unreliable quantification (Ct > 37) were excluded from further analysis, leaving a working set of 249 miRNAs. Relative miRNA expression was calculated using the 2^(-∆∆Ct) method. Normalization was performed with miR-484 as this miRNA was found to be the most stably expressed in all the samples.

Identification of miRNAs associated with relapse

The potential association between the 249 miRNAs and relapse was analyzed with the class comparison tool from BRB Array tools. A random-variance t-test [29] was used to detect miRNAs that were differentially expressed in relapsed vs non-relapsed patients.

Validation of miRNAs in the entire cohort

The miRNAs related to relapse were then used to evaluate TTR in the entire cohort of 50 patients using individual TaqMan microRNA assays (Applied Biosystems) in the ABIPrism 7500 Sequence Detection System (Applied Biosystems) as previously described [28].

Exosome isolation, characterization and miRNA cargo

Exosome isolation was performed from 250μL of plasma samples by ultracentrifugation as previously described [30]. Briefly, sequential centrifugation at 4ºC at 300G 5 min, followed by 2,500G 20 min and finally, 10,000G 30 min, followed by ultracentrifugation at 100,000G 2 hours. Then the pellet was washed with DPBS and ultracentrifuged again at 100,000G 1 hour in a Sorvall MX Plus Micro-Ultracentrifuge with S140AT Rotor and Polycarbonate Tubes (Thermo Scientific).

Exosome characterization was done by two methods: 1) Cryo transmission electron microscopy (cryo-TEM) in a Jeol JEM 2011 transmission electron microscope at the Microscope Facility of the Autonomous University of Barcelona; and 2) western blot analysis, using the exosome marker TSG101.

For the analysis of exosome miRNA cargo, RNA was purified using miRNeasy Mini Kit (Qiagen) after resuspension of the exosome pellet obtained by ultracentrifugation in 750μl Qiazol. MiRNA expression was analyzed using single TaqMan miRNA assays.

Statistical analyses

All 50 patients were evaluable for TTR, calculated from the date of surgery to the date of relapse or last follow-up. The univariate analysis of TTR according to miRNA expression was performed with the Kaplan-Meier method and compared using the log-rank test. Only covariates significantly associated with outcomes in the univariate analysis (two-sided P value < 0.05) were included in the Cox multivariate regression model. Results were reported as hazard ratios (HR) with their 95% confidence intervals (CI). To identify differences in expression according to two or more characteristics, including the comparison between miRNA levels in MV vs PV, the Students T-Test or ANOVA were used as appropriate.

All statistical analyses were performed with SPSS 22 (SPSS Inc, Chicago, IL), R 2.6.0 Software (Vienna, AU), BRB Array Tools version 3.5.0 software (Richard Simon & BRB-ArrayTools Development Team, http://linus.nci.nih.gov/BRB-ArrayTools.html, National Cancer Institute, Bethesda, MD, USA) and TIGR Multiexperiment viewer version 4.0 software (Dana-Farber Cancer Institute, Boston, MA). Statistical significance was set at P < 0.05.

ACKNOWLEDGMENTS

The authors thank the Servei de Donació del Cos a la Ciència (Body Donation Service) for providing funds for the purchase of laboratory materials. SS and JJC are APIF fellows from University of Barcelona. Thanks to the
“Ajuts de la Universitat de Barcelona per publicar en accés obert” for covering part of the the open access costs of this publication.

CONFLICTS OF INTEREST

There is no conflict of interest.

Editorial note

This paper has been accepted based in part on peer-review conducted by another journal and the authors’ response and revisions as well as expedited peer-review in Oncotarget.

REFERENCES


